Uploaded August 2026 | Updated November 2026, 5 hours ago
A novel treatment combines Rifaximin with timed-release NAC to target E. coli and Klebsiella bacteria residing in gut mucus. This approach aims to improve treatment efficacy, potentially reducing re-treatment frequency and offering a "one and done" solution. #GutHealth #Microbiome #MedicalResearch #NewTherapeutics
A novel treatment combines Rifaximin with timed-release NAC to target E. coli and Klebsiella bacteria residing in gut mucus. This approach aims to improve treatment efficacy, potentially reducing re-treatment frequency and offering a "one and done" solution. #GutHealth #Microbiome #MedicalResearch #NewTherapeutics










